Comment
Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?
- PMID: 9375777
Item in Clipboard
Comment
Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide?
Br J Haematol.
1997 Nov.
No abstract available
Comment in
-
Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin.Br J Haematol. 2000 Mar;108(3):663. doi: 10.1046/j.1365-2141.2000.01901.x. Br J Haematol. 2000. PMID: 10847705 No abstract available.
Comment on
-
Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy.Br J Haematol. 1997 Jul;98(1):240-4. doi: 10.1046/j.1365-2141.1997.2213036.x. Br J Haematol. 1997. PMID: 9233593
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical